Skip to main content

Advertisement

Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer’s disease

Fig. 3

Bexarotene selectively reduces microgliosis and decreases plaque burden in the hippocampus. a Representative hippocampal images stained with Iba1 (green) and 6E10 (red) antibodies from vehicle- or bexarotene-treated animals from each treatment group. b Quantification of the hippocampal (left) and cortical (right) Iba1 or 6E10 immunoreactivity. c Quantification of either the cortical (top) or hippocampal (bottom) Thioflavin-S-positive (ThioS+) dense-core plaques. d ELISA results of Aβ isoforms (1-40 or 1-42) from insoluble (FA, left) or soluble (DEA, right) extracts from the hippocampal and cortical homogenates. *p < 0.05, **p < 0.01, and ***p < 0.001, Student’s t test between groups indicated by brackets. ns = not significant. N = 7 or more animals/group. Image magnification, × 20

Back to article page